Innoviva (INVA) Current Leases (2019 - 2026)
Innoviva's (INVA) quarterly Current Leases came in at $646000.0 in Q1 2026, down 49.53% YoY from $1.3 million in Q1 2025, and up 54.55% on a QoQ basis from $418000.0 in Q4 2025.
Analysis
Innoviva (INVA) Current Leases (2019 - 2026) Analysis & Trends
Innoviva (INVA) has 5 years of Current Leases data on file, last reported at $646000.0 in Q1 2026.
- Quarterly Current Leases fell 49.53% year-over-year to $646000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646000.0 (down 49.53% YoY) and the FY2025 annual result came in at $418000.0, down 73.41% from the prior year.
- Current Leases rose to $646000.0 in Q1 2026, from $418000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.6 million in Q4 2024 to a low of $418000.0 in Q4 2025.
- A 4-year average of $1.0 million and a median of $1.1 million in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases soared 30.24% — and 2025, when it sank 73.41%.
- Tracing INVA's Current Leases over 4 years: stood at $1.2 million in 2023, then soared by 30.24% to $1.6 million in 2024, then slumped by 73.41% to $418000.0 in 2025, then surged by 54.55% to $646000.0 in 2026.
- The last three Current Leases figures came in at $646000.0 (Q1 2026), $418000.0 (Q4 2025), and $680000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 712,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 712,000.00 |
| Mar 31, 2026 | 646,000.00 |
| Dec 31, 2025 | 418,000.00 |
| Sep 30, 2025 | 680,000.00 |
| Jun 30, 2025 | 983,000.00 |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Jun 30, 2019 | 317,000.00 |
| Mar 31, 2019 | 308,000.00 |